$293 Million is the total value of Foresite Capital Management IV, LLC's 17 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
EIDX | New | Eidos Therapeutics, Inc. | $4,985,000 | – | 245,082 | +100.0% | 1.70% | – |
TCDA | New | Tricida, Inc. | $2,243,000 | – | 75,000 | +100.0% | 0.76% | – |
KNSA | New | Kiniksa Pharmaceuticals, Ltd. | $1,639,000 | – | 94,477 | +100.0% | 0.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
Insmed Incorporated | 10 | Q1 2020 | 19.2% |
Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
4 | 2024-04-05 |
13F-HR | 2024-02-13 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-12 |
4 | 2023-05-10 |
4 | 2023-02-22 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.